Long non‐coding RNAs differential expression in breast cancer subtypes: What do we know?

Mathias, Carolina; Zambalde, Érika Pereira; Rask, Philip; Oliveira, Juliana Gomes Ramalho de

doi:10.1111/cge.13502

Cited by 42 publications

(42 citation statements)

References 110 publications

(188 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, this regulatory network could identify novel targets to aid in the development of new drugs to improve the efficacy of breast cancer therapy. However, breast cancer is divided into four main subtypes: Luminal A, luminal B, ERBB2 positive and triple negative, and gene expression profiles are not the same for all these subtypes (44). As all these four subtypes were included in the present study, it would be important to explore the differentially expressed lncRNAs in each subtype of breast cancer, allowing for the identification of more diagnostic and prognostic biomarkers.…”

Section: Discussionmentioning

confidence: 99%

Bioinformatics analysis of prognosis-related long non-coding RNAs in invasive breast carcinoma

Yin

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Breast cancer is one of the most common types of cancer among women worldwide and needs more sensitive prognostic biomarkers to improve its treatment. In the present study, differentially expressed long non-coding RNAs (lncRNAs) in invasive breast carcinoma from The Cancer Genome Atlas and cBioPortal database were investigated, identifying 292 differentially expressed lncRNAs in 1,100 cases. By analyzing the overall survival rate, 10 lncRNAs were significantly correlated with poor prognosis. To explore the underlying molecular mechanisms of the 10 prognosis-related lncRNAs, bioinformatic methods were used to predict the potential target miRNAs, mRNAs and proteins, and to construct a lncRNA-miRNA-mRNA regulatory network and lncRNA-protein interaction network. Finally, the functions of the target genes and proteins were insvestigated using Gene Ontology enrichment and Kyoto Encyclopedia of Genes and Genomes pathway analyses. The results showed that these 10 lncRNAs could be novel prognostic markers for invasive breast carcinoma and the present study aimed to provide novel insight into the diagnosis and treatment of breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Bioinformatics analysis of prognosis-related long non-coding RNAs in invasive breast carcinoma

Yin

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Most of the human RNA transcripts are noncoding RNAs (≥80%) (4,5),which play important functions in the different biological processes (4). Long noncoding RNAs (lncRNAs) are noncoding regulatory RNAs and have 200nt or more in length (4)(5)(6). About 4-9 % of the mammalian genome is transcribed into lncRNAs, which is higher than proteincoding mRNAs, but they have lower expression levels (5).…”

Section: Introductionmentioning

confidence: 99%

“…Long noncoding RNAs have diverse roles in the regulation of tumor suppressor genes and oncogenes through epigenetic, transcriptional, post-transcriptional and translational mechanisms, and the regulation of some signaling pathways in cancers (7). Noncoding RNAs, like some long noncoding RNAs show differential expression between tumor tissues and normal tissues (6). LncRNAs can be categorized into tumor suppressor genes and oncogenes according to their functions and the expression patterns in the tumor tissues (8).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Possible Roles of Long Non-Coding RNAs FOXD2-AS1 and LINC00968 in Breast Cancer: Case-Control Study and in Silico Analysis

Arabpour¹,

Layeghi²,

Majidzadeh‐A³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Breast Cancer (BC) is the most common cancer in women worldwide. Long non-coding RNAs (lncRNAs) are regulatory non-coding transcripts and longer than 200 nucleotides. lncRNAs can affect many biological and pathological processes and dysregulation of them is related and studied in many human diseases like, cancers. We performed this study to evaluate the probable functions of lncRNAs FOXD2-AS1 and LINC00968 in breast cancer. Methods: The tumor tissue and adjacent non-tumor tissue specimens of luminal A and B breast cancer (the most frequent subtypes of breast cancer) were used to analyze the expression of these two lncRNAs, using the qRT-PCR technique. Furthermore, two luminal A breast cancer cell lines, MCF7 and T47D, were used to evaluate the expression of FOXD2-AS1 and LINC00968 compared with control breast cell line, MCF10A. Because of the luminal subtypes are the most frequent subtypes of breast cancer and also the most common subtypes among breast cancer patients, the present study was generally focused on the luminal and breast cancer. Also, some in silico analyses were done according to some databases and software for better understanding about the potential functions of mentioned lncRNAs in breast cancer. Results: Our data indicated the significant upregulation and downregulation of FOXD2-AS1 and LINC00968, respectively, in tumor tissues and breast cancer cell lines (MCF7, T47D). The bioinformatic analyses confirmed the experimental results. FOXD2-AS1 expression was positively associated with p53 protein and LINC00968 expression was negatively associated with tumor stage and lymph node metastasis. According to our findings, LINC00968 might be function as a tumor suppressor gene in breast cancer and this lncRNA might function in some cellular signaling pathways, like PI3K/Akt and Ras signaling pathways based on the co-expressed genes, but more investigations are required. Conclusions: The two mentioned lncRNAs might play roles in breast cancer pathogenesis but more experimental studies are needed to explore the mechanisms of the functions of these two lncRNAs in breast cancer.

show abstract

“…Most of the human RNA transcripts are non-coding RNAs (≥80%) [5,6] which perform important functions in different biological processes [5]. Long non-coding RNAs (lncRNAs) are regulatory non-coding RNAs longer than 200 nucleotides [7]. The number of lncRNAs in mammalian genome is higher than protein-coding mRNAs, but they have lower expression levels and tissue-speci c expression [6].…”

Section: Introductionmentioning

confidence: 99%

Potential role of long non-coding RNA LINC00968 in luminal A and B breast cancers

Arabpour

Layeghi

Majidzadeh‐A

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose Breast Cancer (BC) is the most frequent malignancy among women worldwide. ER+ breast cancers (luminal A and B subtypes) comprise up to 70% of all BC patients. Long non-coding RNAs (lncRNAs) are regulatory non-coding transcripts and longer than 200 nucleotides. LncRNAs can affect many biological and pathological processes and dysregulation of them is related to many human cancers. The potential role of LINC00968 lncRNA in luminal A and B breast cancer pathogenesis is still unclear. Methods Seventy-one pairs of tumor and adjacent non-tumor tissue specimens of luminal A and B breast cancer were used to analyze the expression of LINC00968. Furthermore, two luminal A cell lines, MCF7 and T47D, were used to evaluate the expression of LINC00968 compared with a non-malignant breast cell line, MCF10A. Moreover, we have done multiple bioinformatic analyses for a better understanding of the potential roles of LINC00968 in luminal BC. Results Our data revealed the significant downregulation of LINC00968 in luminal tumor tissues and cell lines. LINC00968 expression was negatively associated with tumor stage and lymph node metastasis. Bioinformatic analyses indicated that LINC00968 might be involved in blood vessel development, angiogenesis, and might be participated in interaction of ECM constituents with cancer cells. LINC00968 might have functions in some cancer-related signaling pathways, like PI3K/Akt, ECM-receptor interaction signaling pathway, and PPAR signaling pathway. Conclusions Downregulation of LINC00968 might promote carcinogenesis of luminal BC. LINC00968 might act as a tumor suppressor gene and might also promote invasion and metastasis of luminal BC.

show abstract

Long non‐coding RNAs differential expression in breast cancer subtypes: What do we know?

Cited by 42 publications

References 110 publications

Bioinformatics analysis of prognosis-related long non-coding RNAs in invasive breast carcinoma

Bioinformatics analysis of prognosis-related long non-coding RNAs in invasive breast carcinoma

The Possible Roles of Long Non-Coding RNAs FOXD2-AS1 and LINC00968 in Breast Cancer: Case-Control Study and in Silico Analysis

Potential role of long non-coding RNA LINC00968 in luminal A and B breast cancers

Contact Info

Product

Resources

About